Latest News and Press Releases

ADELAIDE, Australia, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) is presenting a poster on cancer stem cell antibody BNC101 at the 26th EORTC-NCI-AACR Symposium on...

ADELAIDE, Australia, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) is presenting a poster on anti-anxiety compound BNC210 at the Neuroscience 2014 conference being held by...

Bionomics to accelerate BNC210 development for the treatment of anxiety and depression, approval for clinical trial granted Bionomics has re-acquired sole worldwide rights to develop and...

Progression Free Survival at six months by renal cancer patients increased from 36% to 60% for a patient group defined by four biomarkers 57% of patients had the four biomarkers ADELAIDE,...

Pre-existing business integration and strong synergies Valuable drug libraries and in-house expertise Blue chip medium and large pharma customer base High upside potential with modest...

ADELAIDE, South Australia, Sept. 5, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) has received an Australian R&D Tax Incentive payment of $7.5 million following its FY2014 tax...

*DETAILS FOR 10:30AM AEST WEBCAST BELOW* Agreement to fund development of compounds for cognitive impairment associated with Alzheimer's disease and other conditions of the central nervous...

ADELAIDE, South Australia, April 7, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) is delivering three poster presentations at the 105th Annual American Association for Cancer...

Bionomics to Host Webcast at 6:30pm ET TODAY Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient benefit (progression free...

ADELAIDE, South Australia, March 13, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards...